AGN — Argenica Therapeutics Share Price
Last trade - 00:00- AU$56.52m
- AU$48.09m
- AU$0.06m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 8.57 | ||
| Price to Tang. Book | 8.57 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 612.9 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -112.16% | ||
| Return on Equity | -69% | ||
| Operating Margin | -8020.98% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | n/a | 0 | 0 | 0 | 0.06 | n/a | n/a | 524.88% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Argenica Therapeutics Limited is an Australia-based clinical drug development company. The Company is focused on developing therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. The Company's lead candidate, ARG-007, is a cationic arginine-rich peptide that aims to protect brain cells and reduce cell death following a stroke, and other types of neural injury, in order to minimize the impact of these conditions and improve patient recovery. ARG-007 has been successfully demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE).
Directors
- Geoffrey Pocock NEC
- Liz Dallimore CEO
- Samantha South EDR
- Emma Waldon SEC
- Terry Budge NED
- Liddy McCall NED
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 20th, 2019
- Public Since
- June 11th, 2021
- No. of Shareholders
- 1,517
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 99,150,822
- Address
- 4/117 Broadway, NEDLANDS, 6009
- Web
- https://argenica.com.au/
- Phone
- +61 893293396
- Auditors
- RSM Australia Partners
Upcoming Events for AGN
Similar to AGN
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
As of Today at 19:02 UTC, shares in Argenica Therapeutics are trading at AU$0.57. This share price information is delayed by 15 minutes.
Shares in Argenica Therapeutics last closed at AU$0.57 and the price had moved by +34.12% over the past 365 days. In terms of relative price strength the Argenica Therapeutics share price has outperformed the ASX All Ordinaries Index by +28.29% over the past year.
There is no consensus recommendation for this security.
Argenica Therapeutics does not currently pay a dividend.
Argenica Therapeutics does not currently pay a dividend.
Argenica Therapeutics does not currently pay a dividend.
To buy shares in Argenica Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$0.57, shares in Argenica Therapeutics had a market capitalisation of AU$56.52m.
Here are the trading details for Argenica Therapeutics:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: AGN
Based on an overall assessment of its quality, value and momentum Argenica Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Argenica Therapeutics. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +44.94%.
As of the last closing price of AU$0.57, shares in Argenica Therapeutics were trading +22.69% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Argenica Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.57.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Argenica Therapeutics' management team is headed by:
- Geoffrey Pocock - NEC
- Liz Dallimore - CEO
- Samantha South - EDR
- Emma Waldon - SEC
- Terry Budge - NED
- Liddy McCall - NED